Literature DB >> 1597206

Effect of several antimicrobial agents on ciprofloxacin uptake by human neutrophils.

I García1, A Pascual, E J Perea.   

Abstract

The effect of antimicrobial agent active against anaerobes, gram-positive cocci and fungi on the uptake of ciprofloxacin by human neutrophils (PMNs) was evaluated. In the presence of therapeutic extracellular concentrations of these agents, ciprofloxacin reached high intracellular concentrations [cellular-to-extracellular ratio (C/E) greater than or equal to 2.9], this value being higher in the presence of amphotericin B (C/E 6.3 +/- 0.9). The intracellular penetration of ciprofloxacin was higher when PMNs were stimulated with opsonized zymosan (C/E greater than or equal to 5.6). In summary, none of the antimicrobial agents tested significantly impaired the uptake of ciprofloxacin by human PMNs.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1597206     DOI: 10.1007/bf02098094

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  10 in total

1.  Pharmacokinetics and serum bactericidal activities of quinolones in combination with clindamycin, metronidazole, and ornidazole.

Authors:  M Boeckh; H Lode; K M Deppermann; S Grineisen; F Shokry; R Held; K Wernicke; P Koeppe; J Wagner; C Krasemann
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

2.  Alteration in the pharmacokinetic disposition of ciprofloxacin by simultaneous administration of azlocillin.

Authors:  S L Barriere; D H Catlin; P L Orlando; A Noe; R W Frost
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

3.  Fluorometric measurement of ofloxacin uptake by human polymorphonuclear leukocytes.

Authors:  A Pascual; I Garcia; E J Perea
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

Review 4.  Therapeutic implications of bacteriologic findings in mixed aerobic-anaerobic infections.

Authors:  S M Finegold; H M Wexler
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

5.  The in-vitro activity of ciprofloxacin in combination with other agents against anaerobes of clinical interest.

Authors:  B Watt; F V Brown
Journal:  J Antimicrob Chemother       Date:  1986-05       Impact factor: 5.790

Review 6.  Laboratory survey of fluoroquinolone activity.

Authors:  F Bellido; J C Pechère
Journal:  Rev Infect Dis       Date:  1989 Jul-Aug

7.  In-vitro effects of cilofungin (LY121019), amphotericin B and amphotericin B-deoxycholate on human polymorphonuclear leucocytes.

Authors:  P Van der Auwera; F Meunier
Journal:  J Antimicrob Chemother       Date:  1989-11       Impact factor: 5.790

8.  Effect of ciprofloxacin and ofloxacin on human polymorphonuclear leukocyte activity against staphylococci.

Authors:  A Pascual; L Martínez-Martínez; E J Perea
Journal:  Chemotherapy       Date:  1989       Impact factor: 2.544

9.  Effect of antimicrobial agents on the uptake of ofloxacin and its optically active isomer (-)-ofloxacin by human polymorphonuclear leucocytes.

Authors:  A Pascual; I García; E J Perea
Journal:  J Antimicrob Chemother       Date:  1991-11       Impact factor: 5.790

10.  Clindamycin uptake by human neutrophils.

Authors:  M S Klempner; B Styrt
Journal:  J Infect Dis       Date:  1981-11       Impact factor: 5.226

  10 in total
  2 in total

1.  Synergistic interaction of the triple combination of amphotericin B, ciprofloxacin, and polymorphonuclear neutrophils against Aspergillus fumigatus.

Authors:  Theodouli Stergiopoulou; Joseph Meletiadis; Tin Sein; Paraskevi Papaioannidou; Thomas J Walsh; Emmanuel Roilides
Journal:  Antimicrob Agents Chemother       Date:  2011-09-12       Impact factor: 5.191

Review 2.  Intracellular Penetration and Effects of Antibiotics on Staphylococcus aureus Inside Human Neutrophils: A Comprehensive Review.

Authors:  Suzanne Bongers; Pien Hellebrekers; Luke P H Leenen; Leo Koenderman; Falco Hietbrink
Journal:  Antibiotics (Basel)       Date:  2019-05-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.